Traws Pharma, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate
Traws Pharma, Inc. (TRAW) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate of 122.30% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate · last filed 2026-08-14
- Traws Pharma, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2026-03-31 was 122.30%, a 2.69% increase year-over-year.
- Traws Pharma, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2025-03-31 was 119.10%.
- Traws Pharma, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2023-03-31 was 121.00%, a 0.62% decline year-over-year.
- Traws Pharma, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2022-03-31 was 121.76%.
- Traws Pharma, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2025 was 122.00%, a 3.48% increase from fiscal 2024.
- Traws Pharma, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2024 was 117.90%, a 3.99% decline from fiscal 2023.
- Traws Pharma, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2023 was 122.80%, a 1.40% increase from fiscal 2022.
- Traws Pharma, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2022 was 121.10%, a 9.47% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 9 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | 122.30% 10-Q · filed 2026-08-14 | ||||||
| 2026-03-31 | 122.30% 10-Q · filed 2026-05-15 | ||||||
| 2025-12-31 | 122.00% 10-K · filed 2026-04-15 | ||||||
| 2025-09-30 | 120.47% 10-Q · filed 2025-11-13 | ||||||
| 2025-06-30 | 120.50% 10-Q · filed 2026-08-14 | 120.47% 10-Q · filed 2025-08-14 | |||||
| 2025-03-31 | 119.10% 10-Q · filed 2026-05-15 | ||||||
| 2024-12-31 | 117.90% 10-K · filed 2026-04-15 | ||||||
| 2024-09-30 | 117.90% 10-Q · filed 2025-11-13 | ||||||
| 2023-12-31 | 122.80% 10-K · filed 2025-03-31 | ||||||
| 2023-09-30 | 123.10% 10-Q · filed 2024-11-14 | 123.07% 10-Q · filed 2023-11-14 | |||||
| 2023-06-30 | 121.00% 10-Q · filed 2024-08-15 | ||||||
| 2023-03-31 | 121.00% 10-Q · filed 2024-05-15 | ||||||
| 2022-12-31 | 121.10% 10-K · filed 2024-04-01 | 121.11% 10-K · filed 2023-03-30 | |||||
| 2022-09-30 | 121.72% 10-Q · filed 2023-11-14 | ||||||
| 2022-06-30 | 121.49% 10-Q · filed 2023-08-14 | ||||||
| 2022-03-31 | 121.76% 10-Q · filed 2023-05-15 | ||||||
| 2021-12-31 | 133.77% 10-K · filed 2023-03-30 | ||||||
| 2020-12-31 | 105.14% 10-K · filed 2021-03-18 | ||||||
| 2019-12-31 | 103.01% 10-K · filed 2021-03-18 | ||||||
| 2018-12-31 | 79.42% 10-K · filed 2020-03-27 | ||||||
| 2017-12-31 | 79.02% 10-K · filed 2019-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |